AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$EBS

Williams Paul Anthony sold $20K of EBS

Williams Paul Anthony (SVP, Products Business) sold 3,000 shares of Emergent BioSolutions Inc. (EBS) at $6.53 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Paul Anthony
Published Oct 5, 2026, 1:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EBS
Neutral
high confidence
Mentioned
$EBS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EBSNeutralLow
01

Why it matters

The transaction is modest and pre‑arranged, likely causing negligible price movement.

02

Market read

A small insider sell with limited market impact; primarily of interest to compliance and monitoring teams.

03

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing informational value.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-01

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

SVP sold 3,000 shares for $19,590 via a 10b5-1 plan, reducing his stake to 156,098 shares.

Expected impact

likely slight pressure as market prices in the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a pre‑arranged plan, limiting surprise.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Some traders view any insider sell as a red flag, potentially signaling upcoming issues.

Key entities

  • Officer
    Williams Paul Anthony

    SVP, Products Business at Emergent BioSolutions

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EBS insider trading history →

Related articles

OCT 16
$EBSMed

Why is Emergent Biosolutions stock sliding today?

Emergent Biosolutions (EBS) stock fell 10.3% after announcing CFO Richard Lindahl will step down by December 31, 2026, with Frank Vargo as interim CFO. The company faces financial challenges, competitive pressure, and no permanent CFO appointment yet. EBS trades at $6.15, down from its 52-week high of $14.06. Q3 2026 earnings are scheduled for November 2, 2026.

investing.com5 min
OCT 5
$EBSHigh

Why is Emergent Biosolutions stock surging today?

Emergent Biosolutions (EBS) stock rose 19.6% to $7.57 after a suspected pneumonic plague death in Russia. The company's biodefense portfolio and strong Q2 earnings, with adjusted EPS of $0.60 and revenue of $234.3M, supported the surge. Analysts have a consensus 'Hold' rating with a $10.00 price target. The broader market also gained, with the S&P 500 up 0.7% and Nasdaq up 1.0%.

investing.com2 min